Supply High Quality Breviscapine

I. Overview

1. Chemical Nature and Source
Breviscapine is a flavonoid active ingredient extracted from the Erigeron breviscapus plant (Compositae family), primarily composed of scutellarein-7-glucuronide, a flavonoid glycoside. Its chemical structure features a flavonoid aglycone core with significant biological activity.

2. Physicochemical Properties

• Appearance: Pale yellow to yellow powder, hygroscopic, odorless or slightly salty.
• Solubility: Soluble in methanol, pyridine, dilute alkali solutions; slightly soluble in hot water, ethanol, ethyl acetate; nearly insoluble in water, ether, chloroform, and other organic solvents.
• Stability: Stable under light-protected, dry conditions; requires refrigerated storage (e.g., -20°C).

3. Pharmacological Effects

• Cardiovascular System: Vasodilation (especially cerebral vessels), reduced vascular resistance, increased blood flow; inhibition of platelet aggregation and thrombosis; decreased blood viscosity, improved microcirculation.
• Anti-ischemic and Antioxidant Effects: Enhanced myocardial hypoxia tolerance, reduced lipid peroxidation, and protection of ischemic tissues.
• Others: Boosted phagocytic function of macrophages, immunomodulatory effects.

II. Clinical Applications

1. Indications

• Ischemic Cerebrovascular Diseases: Cerebral thrombosis, cerebral embolism, sequelae of cerebral hemorrhage (e.g., hemiplegia), vertebrobasilar artery insufficiency, etc.
• Cardiovascular Diseases: Coronary heart disease, angina pectoris, myocardial infarction, hyperviscosity syndrome.
• Others: Hypertension, peripheral vascular diseases, microcirculation disorders.

2. Dosage Forms and Administration

• Injections: Intravenous drip, 5–20 mg/time, once daily, 10–15 days as a course.
• Oral Forms: Tablets, drop pills, etc., 40–90 mg/time, three times daily.
• Combination Therapy: Co-administration requires monitoring of coagulation function to avoid excessive anticoagulant or antiplatelet effects.

3. Clinical Studies

• Brain Protection: Significant improvement in neurological deficits post-cerebral infarction, promotion of hemiplegic limb recovery.
• Angina Pectoris: Relief of angina symptoms, reduced nitroglycerin dosage.
• Microcirculation Disorders: Improved limb circulation in patients with diabetic foot, Raynaud's syndrome, etc.